URGO
 

HEALING PEOPLE, IT’S AT THE HEART OF EVERYTHING WE DO

 



DFU e-learning module

DFU e-learning module

It is estimated that one in four people with diabetes will have a diabetic foot ulcer during their lives, as a result of a combination of diabetes-related complications.
 

Module details
Leg Ulcers, Diabetic Foot Ulcers and Pressure Ulcers take over 200 days to heal, despite standard treatment. 200 days with a wound represents a huge burden for patients, for clinicians and for the healthcare economy.

Reducing healing time is the priority.

Urgo Medical offers a range of innovative dressings, compression bandages and hosiery, all designed to improve wound healing and patients’ quality of life. We believe strongly in evidence-based care and pride ourselves on our products having the highest level of clinical evidence available.

Our focus is working in partnership with healthcare professionals to move from managing wounds to healing wounds. We offer market leading education and support through our experienced clinical team to help improve patient outcomes and reduce healing time.

Visit us on Stand 70 to find out how we can support you in implementing evidence-based practice and delivering the best possible outcomes for your patients.
Wound Healing



 
URGO Start Plus Treatment Range
UrgoStart Plus treatment range is indicated at any healing stage for all leg
ulcers, diabetic foot ulcers, pressure ulcers and longstanding acute wounds
.
NICE logo

UrgoStart Plus treatment range is recommended by NICE for the treatment of venous leg ulcers and diabetic foot ulcers1
 
 
Stopwatch
UrgoStart Plus treatment is the only treatment that is clinically proven to reduce healing time2-5
 
 
 
Person
The sooner UrgoStart Plus treatment range is initiated the better the healing outcomes for patients6
 
 
   
URGO Start Plus Range

For more information visit: www.urgostartplus.co.uk



References:
  1. NICE Medical Technology Guidance (MTG242): UrgoStart for treating leg ulcers and diabetic foot ulcers; https://www.nice.org.uk, accessed January 2019.
  2. Münter KC, et al. The reality of routine practice: a pooled data analysis on chronic wounds treated with TLC-NOSF wound dressings. J Wound Care. 2017 Feb; 26 (Sup2): S4-S15. Erratum in: J Wound Care. 2017 Mar 2; 26(3): 153
  3. Meaume S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair Regen. 2012; 20: 4, 500–511.
  4. Meaume S, et al. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomized controlled trial. Journal of Wound Care. 2017; 26 (7): 368-379.
  5. Edmonds M, et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international, multicentre, double-blind, randomised, controlled trial. Lancet Diabetes Endocrinol. 2018 Mar;6(3):186-196.
  6. Lázaro-Martínez JL, et al. Optimal wound closure of diabetic foot ulcers with early initiation of TLC-NOSF treatment: post-hoc analysis of Explorer. Journal of Wound Care 2019 28:6, 358-367.

 

UrgoKTwo provides comfortable, continuous compression. UrgoKTwo is a multicomponent system that combines a long-stretch bandage and a short-stretch bandage, giving you the best of both worlds. UrgoKTwo is for all patients with venous and mixed leg ulcers, with and without oedema.


The Cochrane Review, 2012, recommends multi-component systems, and states that “multicomponent bandages are more effective than single-component bandage systems in healing venous leg” and that “multi-component systems appear to perform better when one component is an elastic bandage.”
 
URGOKTwo


UrgoKTwo formats 

Available in:
 
UrgoKTwo

UrgoKTwo (40 mmHg at the ankle)
For venous leg ulcers

 
  • Available in Latex-Free
  • Available in 8cm, 10cm and 12cm bandage widths
UrgoKTwo Reduced

UrgoKTwo Reduced (20 mmHg at the ankle)
For mixed aetiology leg ulcers

For more information visit: www.urgo.co.uk/197-urgoktwo


References:
  1. Junger M et al. Comparison of interface pressures of three compression bandaging systems. J Wound Care 2009;18(11):474-80
  2. Benigni J-P. et al. Efficacy, safety and acceptability of a new two-layer bandage system for venous leg ulcers. JWC, 2007; 16,9 : 385-390.
  3. European Wound Management Association (EWMA). Management of Patients with Venous Leg ulcers: Challenges and Current Best Practice (multicomponent). J Wound Care. 2016.
  4. Hanna R et al. A comparison of interface pressures of three compression bandage systems. Br J Nurs. 2008 Nov 13 (-26;17(20):S16-24-1



 

UrgoMedical offers a comprehensive range of antimicrobial solutions, indicated for all acute and chronic wounds at risk or with signs of local infection. 



UrgoClean Ag
  • UrgoClean Ag is designed to effectively fight against infection and minimize its reoccurrence
  • UrgoClean Ag is a unique combination of fast and broad antimicrobial action1,2, complete and continuous cleaning action3 and effective and sustained anti-biofilm action4

UrgoTul Silver
  • THE EFFECTIVE ANTIMICROBIAL, PAIN-FREE REMOVAL CONTACT LAYER TO FIGHT AGAINST LOCAL INFECTION
  • Proven Efficacy- Fast and broad spectrum antimicrobial efficacy, including on strains resistant to antibiotics 5
  • Comfort- Sustained action for up to 7 days and atraumatic and pain-free at removal due to the TLC-Ag healing matrix 6
Urgo Clean Ag
References:
  1. UrgoClean Ag, data on file, 2014
  2. Desroche N., et al., Characterization of the antimicrobial spectrum and anti-biofi lm activity of a new silver-containing dressing with poly-absorbent fibres and antimicrobial silver matrix. Poster EWMA 2016
  3. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly-absorbent fibres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September 2016
  4. Desroche N. et al., Comparison of in vitro anti-biofilm activities of a new poly-absorbent dressing with a silver matrix and a silver-containing CMC dressing. Poster EWMA May 2017
  5.  UrgoTul Silver data on file
  6. Dalac S., Sigal L., Addala A., et al Clinical evaluation of a dressing with poly-absorbent fi bres and a silver matrix for managing chronic wounds at risk of infection: a non comparative trial. J Wound Care, Vol 25, No 9, September



 
UrgoTul
Providing a nurturing environment for healing and harm free care for all acute wounds
 
Urgo Tul info
Urgo Tul Family
References:
  1. Meaume et al. The importance of pain reduction through dressing selection in routine wound management: the MAPP study, Journal of Wound Care, 2004, Vol 13, No 10, 409-413.
  2. M. Le Berre, Y. Lurton et al., Pansements imprégnés : tulles/ interfaces. Poster, CPC 2005, Paris.
  3. Parpex P. et al. Management of venous leg ulcers with Cellosorb® Micro-adherent dressing: results of a multi-centre clinical trial. Phlebologie 2010; 63: 76-82.
  4. Meaume S. Urgotul®: a novel non-adherent lipidocolloid dressing. British Journal of Nursing. 2002, Vol 11, N°16.
  5. Bernard FX. , Barrault C. et al., Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloïd dressing. Journal of Wound Care, May 2005; 14 (5) : 215-220. (Study conducted on Urgotul).
  6.  FX. Bernard, F. Juchaux et al., Effets d’un pansement lipido-colloïde sur la production de matrice extracellulaire. Journal des Plaies et Cicatrisations, 2007. (Study conducted on Urgotul).
  7.  Report No. RE/DA/2013-164/LAP.
  8.  Benbow M. A clinical evaluation of Urgotul® to treat acute and chronic wounds. British Journal of Nursing. 2004. Vol 13, N°2: 105-109.
  9.  White R. Supporting evidence - based practice: a clinical review of TLC technology, J Wound Care 2015.
  10.  Meaume S. et al. Optimizing wound care with a new lipido-colloid dressing (Urgotul Duo). British Journal of Nursing 2007; 16(6).